Prior to Adjuvant, Glenn launched and then co-managed the Global Health Investment Fund (GHIF), which was sponsored by the Bill & Melinda Gates Foundation and structured by J.P. Morgan’s Social Finance unit, where Glenn was an Executive Director. He is still active on a number of GHIF projects, including board seats on a number of innovative life sciences companies such as Univercells, Themis, and EuBiologics. Glenn also represented GHIF’s interests as a director at IanTech, which was acquired by Carl Zeiss Meditec in 2018. Prior to his GHIF role, Glenn spent more than a decade as an investment banker at J.P. Morgan, where his practice focused on serving the financing needs of research institutions, charitable foundations, universities, and other non-profit organizations. He earned an AB in public policy from the Woodrow Wilson School of Public & International Affairs at Princeton University.